Figure 3.

The attenuated anti-apoptotic protein level and augmented pro-apoptotic protein level of glioblastoma cells by bevacizumab treatment. (A) U87-MG cells were treated with different concentrations of bevacizumab for 48 h, and then the anti-apoptotic protein contents of Bcl-2 and surviving, and the pro-apoptotic protein contents of Bim, Bax and cleaved caspase-3, −8, and −9, as well as the uncleaved PARP, were assessed by western blot analysis, respectively. GAPDH was used as the loading control. The result was a representative of three independent experiments. (B) The quantification of Bcl-2/Bax ratio and the expression levels of other proteins normalized to GAPDH for result in A. Error bars represented mean ± SD. P-values were determined by one-way ANOVA followed by Tukeys post hoc test. ***P<0.001, **P<0.01. ANOVA, analysis of variance.